Intellia Therapeutics Names John F. Crowley to Board of Directors
05 Octobre 2020 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, has
appointed John F. Crowley to its Board of Directors. Mr.
Crowley is a well-established leader in biotech and pharmaceuticals
and a visionary advocate for the advancement of treatments for
people living with rare diseases. He joins Intellia’s board during
a pivotal transition, as the company expects to begin its first
clinical trial this year.
“We are very pleased to welcome John Crowley to our Board of
Directors. He is widely respected for his work in companies that
have developed transformational treatments for rare diseases.
John’s first-hand experiences as a parent advocate with children
who have Pompe disease will help guide Intellia as we pursue our
mission of developing curative therapies for severe and
life-threatening diseases,” said Intellia President and Chief
Executive Officer, John Leonard, M.D. “Together, with our
experienced and diverse senior leadership team, Intellia’s board of
directors will help us achieve our goals and deliver value to our
patients and our shareholders.”
Mr. Crowley brings relevant experience to Intellia’s board,
having started preeminent biotech companies with successful
programs that transitioned from preclinical to clinical
development, and importantly, a commercialized medicine available
for patients. Since 2005, Mr. Crowley has been chairman and chief
executive officer of Amicus Therapeutics, a global biotechnology
company focusing on developing treatments for rare genetic
diseases. At Amicus, he has managed the company’s growth from a
small start-up to one with operations in more than 30 countries and
a market value of more than $3 billion.
Mr. Crowley became a principal advocate for the treatment of the
severe and often fatal neuromuscular disorder, Pompe disease. In
1998, he left his executive position at a large pharmaceutical
company to co-found Novazyme Pharmaceuticals, which was born out of
his desire to research and develop a treatment for two of his
children who had been diagnosed with Pompe. Mr. Crowley oversaw
Novazyme’s acquisition by Genzyme Corporation (now Sanofi) in 2001
and continued on as a senior vice president, where he played a lead
role in the development of drugs for rare diseases.
He has held governing roles at several nonprofits, including the
Global Genes Project as a founding board member and the Make-A-Wish
Foundation of America as a former national chairman. Mr. Crowley
also is a member of the University Council on Science &
Technology at Notre Dame and a Henry Crown Fellow at the Aspen
Institute. The Crowley family was the recipient of the 2011 Family
Exemplar Award from the University of Notre
Dame.
Mr. Crowley graduated with a B.S. in Foreign Service from
Georgetown University. He earned a J.D. from the University of
Notre Dame Law School and an MBA from Harvard Business School.
Outside of his pioneering work in biotech, Mr. Crowley served as a
commissioned intelligence officer in the U.S. Navy Reserve for more
than a decade, assigned to the U.S. Special Operations Command, and
is a combat veteran of the Global War on Terrorism with service in
Afghanistan.
Additionally, Perry Karsen, has decided to step down from his
board position, effective December 31, 2020, due to other
commitments. Mr. Karsen served as chairman of Intellia’s Board of
Directors from April 2016 through February 2020, including the
company’s 2016 initial public offering. He has
remained a member of the board and served
on the Nominating and Corporate Governance Committee, which he
chaired through February 2020, and the Compensation
Committee.
“For the past five years, Perry was instrumental in helping
Intellia grow from a privately held, start-up biotech to the
publicly traded clinical-stage company it is today,” added Leonard.
“We are grateful for the stewardship, direction and friendship he
brought to our board and our employees. We wish him the very best
in his future endeavors as he applies his leadership to his other
endeavors on the West coast.”
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on
the development of proprietary, potentially curative therapeutics
using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by producing
single-course therapeutics that permanently edit and correct
disease-associated genes, and creating enhanced engineered cells
that can treat oncological and immunological diseases. Intellia’s
combination of deep scientific, technical and clinical development
experience, along with its leading intellectual property portfolio,
puts it in a unique position to unlock broad therapeutic
applications of the CRISPR/Cas9 technology and create new classes
of therapeutic products. Learn more about Intellia
Therapeutics and CRISPR/Cas9 at intelliatx.com. Follow us
on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our CRISPR/Cas9 intellectual property
portfolio; achieve stable or effective genome editing; the timing
and potential achievement of milestones to advance our pipeline and
grow as a company; and the anticipated contribution of the members
of our board of directors and our executives to our operations and
progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies; and
the risk that Intellia’s collaborations with Novartis or Regeneron
or its other ex vivo collaborations will not continue or will not
be successful. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Intellia undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Media:Jennifer Mound SmoterSenior Vice
President
External Affairs &
Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Lynnea OlivarezDirectorExternal Affairs & Communications+1
956-330-1917lynnea.olivarez@intelliatx.com
Investors:Lina LiAssociate DirectorInvestor
Relations+1 857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024